Literature DB >> 18570968

Genetic and phenotypic characterization of sylvatic dengue virus type 2 strains.

Nikos Vasilakis1, Eric B Fokam, Christopher T Hanson, Ethan Weinberg, Amadou A Sall, Stephen S Whitehead, Kathryn A Hanley, Scott C Weaver.   

Abstract

The four serotypes of endemic dengue viruses (DENV) circulate between humans and peridomestic Aedes mosquitoes. At present endemic DENV infect 100 million people per year, and a third of the global population is at risk. In contrast, sylvatic DENV strains are maintained in a transmission cycle between nonhuman primates and sylvatic Aedes species, and are evolutionarily and ecologically distinct from endemic DENV strains. Phylogenetic analyses place sylvatic strains basal to each of the endemic serotypes, supporting the hypothesis that each of the endemic DENV serotypes emerged independently from sylvatic ancestors. We utilized complete genome analyses of both sylvatic and endemic DENV serotype 2 (DENV-2) to expand our understanding of their genetic relationships. A high degree of conservation was observed in both the 5'- and 3'-untranslated genome regions, whereas considerable differences at the nucleotide and amino acid levels were observed within the open reading frame. Additionally, replication of the two genotypes was compared in cultured cells, where endemic DENV strains produced a significantly higher output of progeny in human liver cells, but not in monkey kidney or mosquito cells. Understanding the genetic relationships and phenotypic differences between endemic and sylvatic DENV genotypes may provide valuable insight into DENV emergence and guide monitoring of future outbreaks.

Entities:  

Mesh:

Year:  2008        PMID: 18570968      PMCID: PMC3612928          DOI: 10.1016/j.virol.2008.04.044

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


  103 in total

1.  Conserved RNA secondary structures in Flaviviridae genomes.

Authors:  Caroline Thurner; Christina Witwer; Ivo L Hofacker; Peter F Stadler
Journal:  J Gen Virol       Date:  2004-05       Impact factor: 3.891

2.  Clinical and laboratory observations on patients with primary and secondary dengue type 1 infections with hemorrhagic manifestations in Fiji.

Authors:  T Kuberski; L Rosen; D Reed; J Mataika
Journal:  Am J Trop Med Hyg       Date:  1977-07       Impact factor: 2.345

3.  The use of mosquitoes to detect and propagate dengue viruses.

Authors:  L Rosen; D Gubler
Journal:  Am J Trop Med Hyg       Date:  1974-11       Impact factor: 2.345

4.  Studies on the pathogenesis of dengue infection in monkeys. II. Clinical laboratory responses to heterologous infection.

Authors:  S B Halstead; H Shotwell; J Casals
Journal:  J Infect Dis       Date:  1973-07       Impact factor: 5.226

5.  Mov34 protein from mouse brain interacts with the 3' noncoding region of Japanese encephalitis virus.

Authors:  M Ta; S Vrati
Journal:  J Virol       Date:  2000-06       Impact factor: 5.103

6.  Dengue virus inhibits alpha interferon signaling by reducing STAT2 expression.

Authors:  Meleri Jones; Andrew Davidson; Linda Hibbert; Petra Gruenwald; Joerg Schlaak; Simon Ball; Graham R Foster; Michael Jacobs
Journal:  J Virol       Date:  2005-05       Impact factor: 5.103

7.  Nuclear localization of flavivirus RNA synthesis in infected cells.

Authors:  Pradeep Devappa Uchil; Anil V A Kumar; Vijaya Satchidanandam
Journal:  J Virol       Date:  2006-06       Impact factor: 5.103

8.  The serine protease and RNA-stimulated nucleoside triphosphatase and RNA helicase functional domains of dengue virus type 2 NS3 converge within a region of 20 amino acids.

Authors:  H Li; S Clum; S You; K E Ebner; R Padmanabhan
Journal:  J Virol       Date:  1999-04       Impact factor: 5.103

9.  An external loop region of domain III of dengue virus type 2 envelope protein is involved in serotype-specific binding to mosquito but not mammalian cells.

Authors:  Jan-Jong Hung; Meng-Ti Hsieh; Ming-Jer Young; Chuan-Liang Kao; Chwan-Chuen King; Wen Chang
Journal:  J Virol       Date:  2004-01       Impact factor: 5.103

10.  Vector competence of Aedes aegypti populations from Senegal for sylvatic and epidemic dengue 2 virus isolated in West Africa.

Authors:  Mawlouth Diallo; Yamar Ba; Ousmane Faye; Mouhamadou Lamine Soumare; Ibrahima Dia; Amadou Alpha Sall
Journal:  Trans R Soc Trop Med Hyg       Date:  2008-05       Impact factor: 2.184

View more
  28 in total

1.  Sylvatic dengue viruses share the pathogenic potential of urban/endemic dengue viruses.

Authors:  Nikos Vasilakis; Jane Cardosa; Mawlouth Diallo; Amadou A Sall; Edward C Holmes; Kathryn A Hanley; Scott C Weaver; Javier Mota; Rebeca Rico-Hesse
Journal:  J Virol       Date:  2010-04       Impact factor: 5.103

2.  Structure and function analysis of therapeutic monoclonal antibodies against dengue virus type 2.

Authors:  Soila Sukupolvi-Petty; S Kyle Austin; Michael Engle; James D Brien; Kimberly A Dowd; Katherine L Williams; Syd Johnson; Rebeca Rico-Hesse; Eva Harris; Theodore C Pierson; Daved H Fremont; Michael S Diamond
Journal:  J Virol       Date:  2010-06-30       Impact factor: 5.103

Review 3.  Fever from the forest: prospects for the continued emergence of sylvatic dengue virus and its impact on public health.

Authors:  Nikos Vasilakis; Jane Cardosa; Kathryn A Hanley; Edward C Holmes; Scott C Weaver
Journal:  Nat Rev Microbiol       Date:  2011-06-13       Impact factor: 60.633

4.  Antiviral activity of human OASL protein is mediated by enhancing signaling of the RIG-I RNA sensor.

Authors:  Jianzhong Zhu; Yugen Zhang; Arundhati Ghosh; Rolando A Cuevas; Adriana Forero; Jayeeta Dhar; Mikkel Søes Ibsen; Jonathan Leo Schmid-Burgk; Tobias Schmidt; Madhavi K Ganapathiraju; Takashi Fujita; Rune Hartmann; Sailen Barik; Veit Hornung; Carolyn B Coyne; Saumendra N Sarkar
Journal:  Immunity       Date:  2014-06-12       Impact factor: 31.745

5.  Infection dynamics of sylvatic dengue virus in a natural primate host, the African Green Monkey.

Authors:  Kathryn A Hanley; Mathilde Guerbois; Tiffany F Kautz; Meredith Brown; Stephen S Whitehead; Scott C Weaver; Nikos Vasilakis; Preston A Marx
Journal:  Am J Trop Med Hyg       Date:  2014-08-04       Impact factor: 2.345

Review 6.  Fever versus fever: the role of host and vector susceptibility and interspecific competition in shaping the current and future distributions of the sylvatic cycles of dengue virus and yellow fever virus.

Authors:  Kathryn A Hanley; Thomas P Monath; Scott C Weaver; Shannan L Rossi; Rebecca L Richman; Nikos Vasilakis
Journal:  Infect Genet Evol       Date:  2013-03-20       Impact factor: 3.342

7.  Emergence potential of sylvatic dengue virus type 4 in the urban transmission cycle is restrained by vaccination and homotypic immunity.

Authors:  Anna P Durbin; Sandra V Mayer; Shannan L Rossi; Irma Y Amaya-Larios; Jose Ramos-Castaneda; Eng Eong Ooi; M Jane Cardosa; Jorge L Munoz-Jordan; Robert B Tesh; William B Messer; Scott C Weaver; Nikos Vasilakis
Journal:  Virology       Date:  2013-02-26       Impact factor: 3.616

Review 8.  Factors shaping the adaptive landscape for arboviruses: implications for the emergence of disease.

Authors:  Lark L Coffey; Naomi Forrester; Konstantin Tsetsarkin; Nikos Vasilakis; Scott C Weaver
Journal:  Future Microbiol       Date:  2013-02       Impact factor: 3.165

9.  Detection and serotyping of dengue virus in serum samples by multiplex reverse transcriptase PCR-ligase detection reaction assay.

Authors:  S Das; M R Pingle; J Muñoz-Jordán; M S Rundell; S Rondini; K Granger; G-J J Chang; E Kelly; E G Spier; D Larone; E Spitzer; F Barany; L M Golightly
Journal:  J Clin Microbiol       Date:  2008-08-06       Impact factor: 5.948

10.  Lineage II of Southeast Asian/American DENV-2 is associated with a severe dengue outbreak in the Peruvian Amazon.

Authors:  Maya Williams; Sandra V Mayer; William L Johnson; Rubing Chen; Evgeniya Volkova; Stalin Vilcarromero; Steven G Widen; Thomas G Wood; Luis Suarez-Ognio; Kanya C Long; Kathryn A Hanley; Amy C Morrison; Nikos Vasilakis; Eric S Halsey
Journal:  Am J Trop Med Hyg       Date:  2014-07-07       Impact factor: 2.345

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.